home / stock / vyne / vyne news

VYNE News and Press, VYNE Therapeutics Inc Com From 02/27/24

Stock Information
Company Name: VYNE Therapeutics Inc Com
Stock Symbol: VYNE
Market: NASDAQ
Menu
VYNE VYNE Quote VYNE Short VYNE News VYNE Articles VYNE Message Board
Get VYNE Alerts

News, Short Squeeze, Breakout and More Instantly...
VYNE - VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium

Oral presentation on March 7, 2024 will review positive safety and efficacy data for novel BET inhibitor VYN201 BRIDGEWATER, N.J., Feb. 27, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceu...
VYNE - VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

BRIDGEWATER, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory co...

VYNE - Vyne reports positive data from Phase 1b study for vitiligo drug

2024-01-10 18:39:48 ET More on VYNE Therapeutics Vyne Therapeutics jumps 52% on positive data from trials and $88M financing Seeking Alpha’s Quant Rating on VYNE Therapeutics Historical earnings data for VYNE Therapeutics Financial information for VYNE...

VYNE - VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo

VYN201 demonstrated positive effect on key biomarkers relevant to vitiligo Data supports VYN201’s rapid onset of action and previously announced positive clinical results Program is on track for Phase 2b initiation in Q2 BRIDGEWATER, N.J., Jan. 10, 2024 (GLOBE NEW...
VYNE - VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors

BRIDGEWATER, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory con...

VYNE - VYNE Therapeutics says director Lepore buys 13K shares in co

2023-11-20 11:51:49 ET More on VYNE Therapeutics Vyne Therapeutics jumps 52% on positive data from trials and $88M financing Seeking Alpha’s Quant Rating on VYNE Therapeutics For further details see: VYNE Therapeutics says director Lepore buys 13K shares i...

VYNE - VYNE Therapeutics files to sell 36.27M shares for holders

2023-11-13 17:18:11 ET More on VYNE Therapeutics Vyne Therapeutics jumps 52% on positive data from trials and $88M financing Seeking Alpha’s Quant Rating on VYNE Therapeutics Historical earnings data for VYNE Therapeutics Financial information for VYNE...
VYNE - VYNE Therapeutics GAAP EPS of -$2.01, revenue of $0.1M

2023-11-13 08:43:06 ET More on VYNE Therapeutics Vyne Therapeutics jumps 52% on positive data from trials and $88M financing Seeking Alpha’s Quant Rating on VYNE Therapeutics Historical earnings data for VYNE Therapeutics Financial information for VYNE...

VYNE - VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Transformative capital raise of $88.2 million from leading healthcare investors provides funding for BET inhibitor programs through the end of 2025 Phase 2b preparatory activities progressing for VYN201 in nonsegmental vitiligo following positive Phase 1b results On track for VY...

VYNE - Expected US Company Earnings on Thursday, November 9th, 2023

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...
Previous 10 Next 10